Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Glaukos Corporation Common Stock
(NY:
GKOS
)
109.70
-3.33 (-2.95%)
Streaming Delayed Price
Updated: 1:01 PM EST, Feb 11, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Glaukos Corporation Common Stock
< Previous
1
2
3
4
5
6
Next >
Glaucoma Is The Second Leading Cause Of Blindness Globally – Skye Bioscience Appears To Be Making Rapid Progress In The Development Of Their Candidate To Treat It
↗
March 09, 2023
Biomed company Skye Bioscience (OTCQB: SKYE) has seen positive results in its clinical research so far and is preparing for the next stage in the development of its therapy for eye disease.
Via
Benzinga
NVIDIA To Rally Over 20%? Here Are 10 Other Analyst Forecasts For Thursday
↗
February 23, 2023
Goldman Sachs boosted the price target for Vir Biotechnology, Inc. (NASDAQ: VIR) from $41 to $53. Goldman Sachs analyst Paul Choi maintained a Buy rating on the stock. Vir Biotechnology shares rose...
Via
Benzinga
Earnings Preview For Glaukos
↗
February 21, 2023
Via
Benzinga
Analyst Expectations for Glaukos's Future
↗
December 28, 2022
Via
Benzinga
10 Analysts Have This to Say About Glaukos
↗
December 28, 2022
Via
Benzinga
What 10 Analyst Ratings Have To Say About Glaukos
↗
December 28, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 22, 2022
↗
December 22, 2022
Via
Benzinga
7 Analysts Have This to Say About Glaukos
↗
December 12, 2022
Via
Benzinga
Analyst Ratings for Glaukos
↗
December 12, 2022
Via
Benzinga
Skye Bioscience (OTCQB: SKYE) Heads Into 2023 As A Clinical-Stage Company After Dosing Its First Human Participants
↗
December 22, 2022
This year has been quite busy for Skye Bioscience Inc. (OTCQB: SKYE).
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 19, 2022
↗
December 19, 2022
Via
Benzinga
Moderna To Rally Over 42%? Here Are 10 Other Price Target Changes For Monday
↗
December 19, 2022
Morgan Stanley cut VTEX (NYSE: VTEX) price target from $7 to $5. Morgan Stanley analyst Cesar Medina downgraded the stock from Overweight to Equal-Weight. VTEX shares fell 4.9% to close at $3.52 on...
Via
Benzinga
Where Glaukos Stands With Analysts
↗
December 12, 2022
Via
Benzinga
What 4 Analyst Ratings Have To Say About Glaukos
↗
November 03, 2022
Analysts have provided the following ratings for Glaukos (NYSE:GKOS) within the last quarter:
Via
Benzinga
Needham Says Recent Launches To Drive Market Share Recovery For This Eye-Focused MedTech Stock
↗
October 04, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 12, 2022
↗
December 12, 2022
Via
Benzinga
Kellogg, Palo Alto Networks, Roku And Other Big Losers From Thursday
↗
November 04, 2022
U.S. stocks closed lower on Thursday, with the Dow Jones dropping more than 100 points. Here is the list of some big stocks recording losses in the previous session.
Via
Benzinga
Glaukos Shares Pop After Positive Data From Ocular Pressure Candidate
↗
September 07, 2022
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
↗
September 29, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Why IMARA Jumped Around 75%; Here Are 54 Biggest Movers From Yesterday
↗
September 08, 2022
Gainers
Via
Benzinga
Glaukos Inks Licensing Pact For Rare Eye Disorder Treatment
↗
August 24, 2022
Via
Benzinga
Important Biotech Catalysts For September 7, 2022 - End Of The Day Summary
↗
September 07, 2022
Via
Benzinga
Dow Jumps 450 Points; UiPath Shares Slide
↗
September 07, 2022
U.S. stocks traded higher toward the end of trading, with the Dow Jones adding around 450 points on Wednesday.
Via
Benzinga
Dow Up 249 Points, Nasdaq Set To Snap Skid
↗
September 07, 2022
Stocks are charging higher this afternoon, though investors are still awaiting the release of the Federal Reserve's Beige Book.
Via
Talk Markets
Why Korn Ferry Is Trading Lower By Over 8%, Here Are 40 Stocks Moving In Wednesday's Mid-Day Session
↗
September 07, 2022
Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) jumped 64% to $0.1199. Allena Pharmaceuticals shares dipped over 30% on Tuesday after the company announced it has filed for bankruptcy.
Via
Benzinga
Coupa Software, Glaukos And Some Other Big Stocks Moving Higher On Wednesday
↗
September 07, 2022
Via
Benzinga
What's Going On With Glaukos Shares?
↗
September 07, 2022
Glaukos Corp (NYSE: GKOS) shares are trading higher by 1.87% to $49.00 Wednesday morning after the company announced topline data for both Phase 3 pivotal trials of iDose TR that successfully achieved...
Via
Benzinga
Glaukos Stock Scores Rising Price Performance With Jump To 91 RS Rating
↗
August 16, 2022
On Tuesday, Glaukos stock hit an key technical milestone, with its Relative Strength Rating climbing to 91, up from 87 the day before.
Via
Investor's Business Daily
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
↗
August 03, 2022
Via
Benzinga
Glaukos: Q2 Earnings Insights
↗
August 03, 2022
Glaukos (NYSE:GKOS) reported its Q2 earnings results on Wednesday, August 3, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Glaukos missed estimated earnings by...
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.